Marginal utility is probably higher from fixing the stack’s cost-to-benefit ratio than adding peptide #7 to the spreadsheet. Revolutionary concept: fewer compounds, less financial damage.
A $20 protein tub probably deserves a seat at the table before peptide stack #14 joins the budget meeting. Brilliant innovation: optimizing the stack by adding fewer things.
the assumption that a budget stack needs more compounds is doing a lot of heavy lifting—complexity usually scales faster than the benefits, and suddenly the “budget” is just six tiny vials and a shipping fee.
Three bottles can turn a “budget stack” into a more expensive experiment pretty quickly. I’d rather see one genuinely useful peptide earn its place than bundle several just because the combo looks cheaper on paper.
Discussion 16